摘要
目的探讨来氟米特的安全性,为临床更加安全有效地使用该药提供有价值的信息。方法通过维普资讯《中国科技期刊数据库》,检索2005-2010年发表的有关来氟米特的临床研究文献。筛选用药中进行不良反应监测的文献,进行汇总分析。结果获得符合条件的病例报道45篇,涉及病例2540例。发生不良反应的病例147例,占全部病例的5.79%。来氟米特的不良反应以皮肤疾病以及腹泻腹痛、肝功能障碍发生率较高,分别是25.85%、20.40%、12.24%。结论来氟米特主要不良反应是皮肤疾病、腹泻腹痛和肝功能障碍,临床安全性较好。
Objective To analyze the safety of leflunomide and provide valuable information for safe and effective using of leflunomide in clinic.Methods The clinical research articles about leflunomide were searched by《Chinese Science and Technology Periodical Database》from 2005 to 2010.The articles were screened for those about monitoring the adverse drug reactions（ADR） of leflunomide.Results 147（5.79% ） ADR cases were appeared in 45 articles,which totally involved 2540 cases.The occurrence of skin disorders,diarrhea and liver dysfunction was 25.85%,20.40% and 12.24% respectively.Conclusion The skin disorders,diarrhea and liver dysfunction are the mostly ADR of leflunomide.Leflunomide is comparatively safe in clinical.
出处
《临床合理用药杂志》
2010年第20期8-9,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
来氟米特
药品不良反应
文献分析
Leflunomide
Adverse drug reactions
Document analysis
